Close Menu

NEW YORK (GenomeWeb) – NanoString Technologies announced after the close of the market on Monday that it is planning a public offering of 4.5 million shares of its common stock.

The company itself will offer and sell 2.5 million shares, while one of its stockholders, Clarus Lifesciences, will offer and sell the other 2 million shares. NanoString also said it will grant the underwriters a 30-day option to purchase up to 675,000 additional shares. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.